NEW YORK, Jan. 3 (GenomeWeb News) - Faced with delisting from the Nasdaq exchange, Large Scale Biology has shuttered its operations, including its proteomics subsidiary, Predictive Diagnostics, GenomeWeb News has learned.
LSBC disclosed its plan in a filing with the Securities Exchange Commission. Though the filing did not mention Predictive Diagnostics' fate, when GenomeWeb News called the company for details today a recorded message said, "Effective December 23, 2005, Predictive Diagnostics, Inc. has ceased operations. Calls to this number will not be returned."
GenomeWeb News has reported LSBC's financial woes in the past. After its stock price plummeted to less than $1 per share in June, Nasdaq threatened to delist the company unless the share price went back up in 180 days.
According to the SEC filing, LSBC's stock ceased trading at the end of trading on Dec. 23.